TC
Therapeutic Areas
Gibson Oncology Pipeline
| Drug | Indication | Phase |
|---|---|---|
| LMP744 | Glioblastoma | Phase 2 |
| LMP400 | Solid Tumors, Lymphomas, PTEN-deficient tumors | Phase 1 |
| LMP776 | Solid Tumors, Lymphomas | Phase 1 |
| Aza Indenoisoquinolines | Oncology | Pre-clinical |
Leadership Team at Gibson Oncology
MC
Mark C. Rogers, MD, MBA
Founder and Executive Chair
RB
Randall B. Riggs
President and Chief Executive Officer
EL
Elizabeth London Rogers, MD
Founder and Chief Operations Officer
CT
Clifford T. Solomon, MD
Founder and Chief Medical Officer
MS
Mark S. Cushman, PhD., PharmD
Founder and Chief Scientific Officer